Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 8;13:17–24. doi: 10.2147/JPR.S213820

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Kfoury et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) Mechanical pain threshold in the two groups after parietal nerve block. The bupivacaine group shows a significant increase in threshold as compared to the placebo group. Box plots are median, 10th, 25th, 75th and 90th percentile, dots are lower and upper range. *p=0.007 vs control. (B) c-Fos reactive nuclei 2 hrs after injury in the dorsal horn at the T9-T10 level in two representative animals (control group in the upper part and bupivacaine group in the lower part). (C) Number of c-Fos immunoreactive nuclei in the spinal cord measured at different metameric levels. c-Fos reactive nuclei were significantly less numerous in the bupivacaine group than in the control group from T5 to L3. *p<0.0001 bupivacaine group vs control group.